Working... Menu
Trial record 30 of 74 for:    "Andersen-Tawil syndrome" OR "Long QT Syndrome"

Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00588965
Recruitment Status : Completed
First Posted : January 9, 2008
Results First Posted : July 30, 2013
Last Update Posted : July 30, 2013
Information provided by (Responsible Party):
Elizabeth S. Kaufman, MD, MetroHealth Medical Center

Brief Summary:

Background. In congenital long QT syndrome type 1 (LQT1), episodes of ventricular tachycardia are usually triggered by exercise and can be prevented in most patients by beta-blocker therapy. In addition, LQT1 associated with a normal resting QT interval can be unmasked by the abnormal QT response to exercise testing (failure of the QT interval to shorten normally). Preliminary data from our laboratory show that the exercise QT intervals of patients with LQT1 are partially normalized by beta-blocker therapy. It is still currently not known if beta-blockers modify the QT/heart rate relationship (a primary effect on repolarization) or if the "normalizing" effect is due to the inability of subjects on beta-blockers to attain sufficiently high workloads (due to reduced heart rate) for prolongation to occur. Moreover, the physiologic response of the exercise QT interval to beta-blockers in healthy control subjects is not known.

Objective. The objective of this study is to define the impact of beta-blocker therapy on the QT response to exercise and recovery in normal subjects.

Methods. Approximately 36 healthy adult subjects age-matched to previously studied LQT1 subjects will undergo 1) screening history, 2) two weeks of beta-blocker therapy ending in an exercise test, and 3) two weeks of placebo therapy ending in an exercise test. Beta blocker and placebo will be given in random order in a double-blind fashion. The QT response to exercise and recovery will be compared between drug-free and beta-blocker-treated states. These data will be compared to those previously collected for LQT1 subjects.

Implications. These results will provide new information about the effect of beta-blocker therapy on repolarization parameters in normal subjects, and will provide a context in which to interpret the previous findings that beta-blocker administration modifies the QT response to exercise in LQT1 subjects.

Condition or disease Intervention/treatment Phase
Long QT Syndrome Cardiac Repolarization Drug: Placebo Drug: Propranolol LA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Study Start Date : August 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Arm Intervention/treatment
Placebo Comparator: 1
Subjects are assigned to placebo.
Drug: Placebo
Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.

Active Comparator: 2
Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
Drug: Propranolol LA
Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.

Primary Outcome Measures :
  1. QTc Response to Exercise on Versus Off Beta-blocker. [ Time Frame: 2 weeks on each treatment then exercise test ]
    To minimize the effect of heart rate on QT, QT was measured at heart rates between 100 and 110 beats per minute during exercise (on and off beta-blocker) and during recovery (on and off beta-blocker).

Secondary Outcome Measures :
  1. Tpeak-end Interval (Tpe) [ Time Frame: Measured after 2 weeks on each intervention ]
    Tpeak-end interval was measured at rest, exercise, and recovery on placebo and on propranolol.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy normal adults, age- and gender-matched to previously studied LQT1 subjects

Exclusion Criteria:

  • Cardiac disease
  • Diabetes
  • Hypertension
  • Severe allergic reaction
  • Asthma requiring treatment
  • Use of medications other than oral contraceptives, acetaminophen, nonsteroidal anti-inflammatory drugs, or synthroid or other thyroid medications
  • Pregnancy (subjects will be asked if they are pregnant)
  • Inability to sign informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00588965

Sponsors and Collaborators
MetroHealth Medical Center
Layout table for investigator information
Principal Investigator: Elizabeth S Kaufman, MD MetroHealth Medical Center

Layout table for additonal information
Responsible Party: Elizabeth S. Kaufman, MD, Professor, Case Western Reserve University, MetroHealth Medical Center Identifier: NCT00588965     History of Changes
Other Study ID Numbers: IRB07-00418
NIH grant, GCRC MO1 RR000080
First Posted: January 9, 2008    Key Record Dates
Results First Posted: July 30, 2013
Last Update Posted: July 30, 2013
Last Verified: July 2013

Keywords provided by Elizabeth S. Kaufman, MD, MetroHealth Medical Center:
QT interval

Additional relevant MeSH terms:
Layout table for MeSH terms
Long QT Syndrome
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities
Pathologic Processes
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents